Comparative Pharmacology
Head-to-head clinical analysis: LOTRIMIN ULTRA versus LOTRISONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LOTRIMIN ULTRA versus LOTRISONE.
LOTRIMIN ULTRA vs LOTRISONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Butenafine hydrochloride is a synthetic antifungal agent that inhibits the enzyme squalene epoxidase, thereby blocking the biosynthesis of ergosterol, an essential component of fungal cell membranes, leading to fungal cell death.
Lotrisone combines betamethasone dipropionate, a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to reduce inflammation, and clotrimazole, an imidazole antifungal that inhibits CYP51 (lanosterol 14alpha-demethylase), disrupting ergosterol synthesis and fungal cell membrane integrity.
Adults: Apply butenafine hydrochloride 1% cream topically once daily for 7 days for tinea pedis; for tinea cruris and tinea corporis, apply once daily for 14 days.
Apply a thin film to affected skin areas twice daily, morning and evening, for 2 weeks.
None Documented
None Documented
Terminal elimination half-life is approximately 24-48 hours (range 20-50 hours), supporting once-daily topical application.
Clotrimazole: 3.5-6 hours (topical, minimal systemic absorption); betamethasone dipropionate: approximately 4-6 hours for betamethasone after hydrolysis.
Primarily fecal (approx. 80%) as unchanged drug and metabolites; renal excretion accounts for <10% of the dose.
Clotrimazole: <0.5% of dose excreted unchanged in urine; betamethasone dipropionate: primarily renal (<5% unchanged) and biliary/fecal (35-50% as metabolites).
Category C
Category C
Topical Antifungal
Topical Antifungal/Corticosteroid Combination